Lupus Erythematosus (LE) Is Increasing, and Many Companies Are Investigating Lupus Erythematosus LE as an Expansion Indication.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43396) has announced the addition of Decision Resources Report 'Emerging Therapies to Treat Lupus Erythematosus' to their offering. Introduction Lupus Erythematosus (LE), a family of chronic autoimmune diseases, ranges from skin disease to life-threatening systemic disease. Multiple therapy options are necessary, even for patients with similar symptomsCoand there is great need for agents that can control the complications of systemic disease. LE therapy development is increasing, and many companies are investigating LE as an expansion indication. Get the Answers You Need to Shape Your Strategy The small lupus erythematosus (LE) patient population poses challenges to companies that are developing agents for this indication: enrolment for clinical trials can be difficult, and the sales potential of these agents is limited. What are companies doing to surmount these challenges? Although effective, few existing agents for cutaneous LE are considered safe enough for long-term use. An effective agent that is safe for prolonged treatment will have a significant competitive advantage. Which agent now in development has the best chance to satisfy this need? Is any agent currently in development likely to displace current first-line therapies? Because of the heterogeneous nature of systemic LE, the market can support many agents. But owing to the number of effective generics available, emerging agents must prove their greater efficacy and safety to ensure adoption. What are the advantages and disadvantages of the emerging therapies' modes of action? How soon are new therapies likely to reach the market? What are their prospects for success in competition with generics and established therapies? Scope Etiology, pathophysiology, and prevalence: relationship of cutaneous lupus erythematosus (CLE) to systemic lupus erythematosus Systemic Lupus Erythematosus Definition Systemic lupus erythematosus (also called lupus or SLE) is a disease where a person's immune system attacks and injures the body's own organs and tissues. Almost every system of the body can be affected by SLE. (SLE); prevalence of systemic lupus erythematosus in the three major-market regions by gender. Current therapies: overview of leading therapies for CLE and for SLE. Indications covered: CLE (discoid discoid /dis·coid/ (dis´koid) 1. disk-shaped. 2. a dental instrument with a disklike or circular blade. 3. a disk-shaped dental excavator designed to remove the carious dentin of a decayed tooth. LE), acute CLE, subacute CLE, and SLE. Emerging therapies: overview of agents for development for CLE and SLE; late-stage agents are discussed in detail. Market outlook: challenges that emerging agents will face and their prospects for success. Therapies mentioned inside this report include: * Abatacept * Abetimus sodium * Acitretin * Amcinonide * ASF-1096 * Azathioprine azathioprine: see metabolite. * Belimumab * Betamethasone betamethasone /be·ta·meth·a·sone/ (ba?tah-meth´ah-son) a synthetic glucocorticoid, the most active of the antiinflammatory steroids; used topically as the benzoate, dipropionate, or valerate salts as an antiinflammatory, topically or * diproprionate * Celecoxib * Chloroquine chloroquine /chlo·ro·quine/ (klor´o-kwin) an antiamebic and anti-inflammatory used in the treatment of malaria, giardiasis, extraintestinal amebiasis, lupus erythematosus, and rheumatoid arthritis; used also as the hydrochloride and * Clobetasol proprionate * Cyclophosphamide cyclophosphamide /cy·clo·phos·pha·mide/ (-fos´fah-mid) a cytotoxic alkylating agent of the nitrogen mustard group; used as an antineoplastic, as an immunosuppressant to prevent transplant rejection, and to treat some diseases * Dapsone dapsone /dap·sone/ (dap´son) an antibacterial bacteriostatic for a broad spectrum of gram-positive and gram-negative organisms; used as a leprostatic, as a dermatitis herpetiformis suppressant, and in the prophylaxis of falciparum * Diflorasone diacetate * Edratide * Efalizumab * Epratuzumab * Etretinate * Hydroxychloroquine * Intravenous gamma * globulin globulin, any of a large family of proteins of a spherical or globular shape that are widely distributed throughout the plant and animal kingdoms. Many of them have been prepared in pure crystalline form. * Isotretinoin isotretinoin /iso·tret·i·noin/ (i?so-tret´in-o-in) a synthetic form of retinoic acid, used orally to clear cystic and conglobate acne. i·so·tret·i·no·in n. * Lefl unomide * Methotrexate * Mycophenolate mofetil * Pimecrolimus * Prasterone * Rituximab * Sirolimus * Tacrolimus * Thalidomide * Triamcinolone acetonide For more information visit http://www.researchandmarkets.com/reports/c43396 Source: Decision Resources |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion